Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Quality of Care: BMT

If you are choosing a transplant center, we know that the issues you must weigh and the decisions you must make are complicated. We are dedicated to answering any questions you may have.

How Do I Know You’re Good At This?

One of the biggest questions may be “how do I know you are good at this?” How well an individual patient does when undergoing a blood or bone marrow transplant depends on a wide range of factors – you must discuss details about your own situation with your doctor.

However, 100-day and one-year survival rates (the proportion of patients that are alive 100 days and one year after transplant) are an indicator of how well a specific transplant center performs. These are statistics that we report to accrediting agencies and insurance plans, and we report this information here to help you make the best decision for yourself and your family. These rates may be affected by the complexity and severity of the cases that the transplant center accepts. We encourage you to ask if you have any questions about our outcomes.

The following is divided according to the types of transplants and the degree of match where donor cells are used.

Terms You Should Know

  • Autologous transplant – a patient's own cells are used
  • Allogeneic transplant – a related or unrelated donor’s cells are used
  • Antigen mismatch – reflects how closely a donor's cells match the patient’s own cells. The greater the mismatch, the greater the risk that the transplant will be rejected.
  • Myeloablative – refers to chemotherapy and/or radiation received before treatment that completely wipes out the patient's own bone marrow
  • Non-myeloablative – a so-called "mini transplant", which uses less intensive chemotherapy and radiation before transplant and does not completely wipe out the patient’s own bone marrow

Statistics for Autologous Transplants

  • Total number of patients in 2007: 64
    100-day survival rate: 95%
  • Total number of patients 2004-2006: 250
    100-day survival rate: 96%
    One-year survival: 86%
  • More Details by Disease (PDF format)

Statistics for Allogeneic Myeloablative Related Donor Transplants

0-1 Antigen Mismatch

  • Total patients in 2007: 14
    100-day survival rate: 93%
  • Total patients 2004-2006: 53
    100-day survival rate: 91%
    One-year survival rate: 68%
  • More Details by Disease (PDF format)

Statistics for Allogeneic Non-myeloablative Related Donor Transplant

0-1 Antigen Mismatch

  • Total patients in 2007: 13
    100-day survival rate: 100%
  • Total patients 2004-2006: 38
    100-day survival rate: 92%
    One-year survival rate: 63%
  • More Details by Disease (PDF format)

Note: Vanderbilt-Ingram Cancer Center does not perform allogeneic myeloablative transplants involving related donors with a greater than 1 antigen mismatch.

Statistics for Allogeneic Unrelated Donor Transplants

  • Total patients in 2007: 15
    100-day survival rate: 100%
  • Total patients 2004-2006: 37
    100-day survival rate: 86%
    One-year survival rate: 62%
  • More Details by Disease (PDF format)

Statistics for Allogeneic Non-myeloablative Unrelated Donor Transplants

  • Total patients in 2007: 12
    100-day survival rate: 67%
  • Total patients 2004-2006: 23
    100-day survival rate: 70%
    One-year survival rate: 39%
  • More Details by Disease (PDF format)

Statistics for Allogeneic Cord Blood (both related and unrelated)

  • Total patients in 2007: 3
    100-day survival rate: 100%
  • Total patients 2004-2006: 5
    100-day survival rate: 80%
    One-year survival rate: 40%
  • More Details by Disease (PDF format)